Literature DB >> 2819937

Radiation protection of murine intestine by WR-2721, 16,16-dimethyl prostaglandin E2, and the combination of both agents.

W R Hanson.   

Abstract

The survival of murine intestinal clonogenic cells (ICC) and the survival of mice after whole-body exposure to 137Cs irradiation were used to measure radiation protection by ethiophos (WR-2721), 16,16-dimethyl prostaglandin E2, and the combination of the two. Doses from 2 to 12.5 mg/mouse of WR-2721 increased cell survival linearly from 3.2 +/- 0.3 in controls given 15.0 Gy to 93.1 +/- 5.2 per jejunal circumference. In contrast, 16,16-dm PGE2 increased ICC survival at 15.0 Gy rapidly from 1 to 10 micrograms/mouse, followed by a plateau up to 100 micrograms/mouse. Animal survival at 6 days (LD50/6) increased from 16.3 +/- 0.4 Gy (95% confidence limits) in controls to 20.3 +/- 0.6 Gy in the PG-treated animals. WR-2721 increased the LD50/6 to 26.1 +/- 1.4 Gy. The dose modification factors were 1.25 and 1.60, respectively. The combination of agents increased ICC survival above that seen with each agent alone up to 8 mg WR-2721, above which no additional protection was seen. Animals given 10 micrograms PG plus 10 mg WR-2721 survived longer than with either agent given alone. The LD50/6 was 36.3 +/- 1.8 Gy for a dose modification factor (DMF) of 2.23. In addition, the slope of the probit curve was reduced from those of each agent alone. PG-induced changes in villus epithelial cell morphology and survival may account, in part, for these observations. The results suggest that either the mechanisms for these two types of radiation protectors are different or they act on separate subcellular targets which are critical to survival from radiation injury.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2819937

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  10 in total

1.  Prostaglandin E2 increases hematopoietic stem cell survival and accelerates hematopoietic recovery after radiation injury.

Authors:  Rebecca L Porter; Mary A Georger; Olga Bromberg; Kathleen E McGrath; Benjamin J Frisch; Michael W Becker; Laura M Calvi
Journal:  Stem Cells       Date:  2013-02       Impact factor: 6.277

2.  Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.

Authors:  Konstantinos H Katsanos; Evangelos Briasoulis; Pericles Tsekeris; Anna Batistatou; Maria Bai; Christos Tolis; Antonio Capizzello; Ioannis Panelos; Vasileios Karavasilis; Dimitrios Christodoulou; Epameinondas V Tsianos
Journal:  J Exp Clin Cancer Res       Date:  2010-06-10

3.  Structural and functional alterations of the gastrointestinal tract following radiation-induced injury in the rhesus monkey.

Authors:  Roy M Vigneulle; Srinivas Rao; Alessio Fasano; Thomas J MacVittie
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

4.  Recovery from hematopoietic injury by modulating prostaglandin E(2) signaling post-irradiation.

Authors:  Jonathan Hoggatt; Pratibha Singh; Kayla N Stilger; P Artur Plett; Carol H Sampson; Hui Lin Chua; Christie M Orschell; Louis M Pelus
Journal:  Blood Cells Mol Dis       Date:  2012-11-30       Impact factor: 3.039

5.  Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats.

Authors:  L R Empey; J D Papp; L D Jewell; R N Fedorak
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

6.  Effect of radiation and radioprotection on small intestinal function in canines.

Authors:  J L Herrera; R M Vigneulle; T Gage; T J MacVittie; J B Nold; A Dubois
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

Review 7.  Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline.

Authors:  Ludy Lutgens; Philippe Lambin
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

Review 8.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

Review 9.  Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Authors:  Michal Hofer; Zuzana Hoferová; Martin Falk
Journal:  Int J Mol Sci       Date:  2017-06-28       Impact factor: 5.923

Review 10.  Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review.

Authors:  Michal Hofer; Zuzana Hoferová; Daniel Depeš; Martin Falk
Journal:  Molecules       Date:  2017-05-19       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.